Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C

Liver International

Volumn 29, Issue 4, 2009, Pages 557-565

  Mirandola, Silvia ^a   Österreicher, Christoph H ^b   Marcolongo, Moira ^a   Datz, Christian ^c   Aigner, Elmar ^c   Schlabrakowski, Anne ^d   Realdon, Stefano ^a   Gerotto, Martina ^a   Alberti, Alfredo ^a   Stickel, Felix ^e  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Krankenhaus Oberndorf   (Austria)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

Genetic risk; Hepatitis C; Lipid metabolism; Metabolic syndrome; Microsomal triglyceride transfer protein; Steatosis

Indexed keywords

APOLIPOPROTEIN A1; GLYCINE; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; THREONINE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; FATTY LIVER; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE;

ADULT; APOLIPOPROTEIN A-I; CARRIER PROTEINS; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIPOPROTEINS, HDL; MALE; MICROSOMES, LIVER; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; RNA, MESSENGER;

EID: 62749100684     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01892.x     Document Type: Article

References (44)

1. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
2. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006; 55: 123-30.
3. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
4. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
5. Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41: 82-7.
6. Leandro G, Mangia A, Hui J, et al. HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
7. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
8. Ryder SD, Irving WL, Jones DA, et al. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53: 451-5.
9. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
10. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. J Hepatol 2003; 38: 75-85.
11. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-6.
12. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
13. Rubbia-Brandt L, Giostra E, Mentha G, et al. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35: 307.
14. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmatic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-5.
15. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-70.
16. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Nat Acad Sci USA 2002; 99: 15669-74.
17. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J 2002; 16: 185-94.
18. Wetterau JR, Zilversmit DB. Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim Biophys Acta 1986; 875: 610-7.
19. Boren J, Veniant MM, Young SG. Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 1998; 101: 1197-202.
20. Nielsen LB, Veniant M, Boren J, et al. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 1998; 98: 13-6.
21. Hussain MM, Jason S, Paul D. Microsomal triglyceride transfer protein and its role in ApoB-lipoprotein assembly. J Lipid Res 2003; 44: 22-32.
22. Berriot-Verrequeaux N, Aggerbeck M, Samson-Bouma M, Wetterau JR. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000; 20: 663-97.
23. Karpe F, Lundahl B, Ehrenborg E, et al. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol 1998; 18: 756-61.
24. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 995-9.
25. Namikawa C, Shu-Ping Z, Vyselaar JR, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004; 40: 781-6.
26. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-9.
27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
28. Athar H, Iqbal J, Jian XC, Hussain MM. A simple, rapid and sensitive fluorescent assay for microsomal triglyceride transfer protein. J Lipid Res 2004; 45: 764-72.
29. Osterreicher CH, Stickel F, Brenner DA. Genomics of liver fibrosis and cirrhosis. Semin Liv Dis 2007; 27: 28-43.
30. Petit JM, Masson D, Minello A, et al. Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients. Mol Genet Metab 2006; 88: 196-8.
31. Joannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genetics 2001; 29: 306-9.
32. Richardson MM, Powell EE, Barrie HD, et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet 2005; 42: E45.
33. Ledmyr H, Karpe F, Lundahl B, Mckinnon M, Skoglund-Andersson C, Ehrenborg E. Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. J Lipid Res 2002; 43: 51-8.
34. Lundahl B, Skoglund-Andersson C, Caslake M, et al. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles. Am J Physiol Endocrinol Metab 2006; 290: E739-45.
35. Gambino R, Cassader M, Pagano G, et al. Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 2007; 45: 1097-107.
36. Zampino R, Ingrosso D, Durante-Mangoni E, et al. Microsomal triglyceride transfer protein (MTP) - 493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat 2008 15 May [Epub ahead of print].
37. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12: 6756-65.
38. Stickel F, Österreicher CH. Genetic factors in alcoholic liver disease. Alcohol Alcohol 2006; 41: 209-24.
39. The international HapMap project. Nature 2003; 426: 789-96.
40. Powell EE, Jonsson JR, Clouston AD. Steatosis: Co-factor in other liver diseases. Hepatology 2005; 42: 5-13.
41. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-7.
42. Lin MCM, Li JJ, Wang EJ, et al. Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB J 1997; 11: 1145-52.
43. Sugimoto T, Yamashita S, Ishigami M, et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol 2002; 36: 157-62.
44. Letteron P, Sutton A, Mansouri A, et al. Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice. Hepatology 2003; 38: 133-40.